ライフサイエンスコーパス: therapeutic strategy

1 nhibitor (SMKI) could be an effective, novel therapeutic strategy.

2 ivity or biased signaling and is a promising therapeutic strategy.

3 ti-bacterial responses and might represent a therapeutic strategy.

4 nd validate riboflavin esters as a potential therapeutic strategy.

5 ver active TH to the brain could be a viable therapeutic strategy.

6 mmation has the potential to be an effective therapeutic strategy.

7 ules has been a long sought-after anticancer therapeutic strategy.

8 mass is still intact, could be a successful therapeutic strategy.

9 ataxin-2 could represent a broadly effective therapeutic strategy.

10 PTEN-deregulated cancers represents a valid therapeutic strategy.

11 in self-aggregation represents an attractive therapeutic strategy.

12 n of TNKS therefore represents an attractive therapeutic strategy.

13 , and patient participation in the long-term therapeutic strategy.

14 y step in Gln metabolism, represent a viable therapeutic strategy.

15 pression in VHL-HBs, offering an alternative therapeutic strategy.

16 unctional macrophages represents a promising therapeutic strategy.

17 -risk group for whom there is controversy on therapeutic strategy.

18 vide a compelling basis for developing novel therapeutic strategies.

19 ls, posing an urgent need for new antifungal therapeutic strategies.

20 an important human pathogen and suggest new therapeutic strategies.

21 t risk of dementia that might facilitate new therapeutic strategies.

22 tify targets for drug intervention and novel therapeutic strategies.

23 of tumours and to discover new biomarkers or therapeutic strategies.

24 fficient vertebrate model for developing PKD therapeutic strategies.

25 eans there is significant unmet need for new therapeutic strategies.

26 genetics, disease modelling, biomarkers, and therapeutic strategies.

27 ated widespread interest in targeting UPR as therapeutic strategies.

28 therapies emphasise the necessity to improve therapeutic strategies.

29 tudy, interaction of pathways, and potential therapeutic strategies.

30 of cardiovascular disease and monitor novel therapeutic strategies.

31 tanding of the aged kidney and lead to novel therapeutic strategies.

32 rcuit function and in the development of new therapeutic strategies.

33 ther elucidating pathophysiologic events and therapeutic strategies.

34 the deadliest malignancies lacking effective therapeutic strategies.

35 role for Muller cells and may inform future therapeutic strategies.

36 ide novel targets for the development of new therapeutic strategies.

37 on with checkpoint blockade therapy or other therapeutic strategies.

38 ct signaling heterogeneity and suggest novel therapeutic strategies.

39 ead to epithelia as an attractive target for therapeutic strategies.

40 opriate platforms for the development of new therapeutic strategies.

41 , and could influence the development of new therapeutic strategies.

42 n of TRPC6 activity and may result in future therapeutic strategies.

43 ferentiation are essential to implement such therapeutic strategies.

44 hat exploit these mechanisms may provide new therapeutic strategies.

45 n in neurons and provides a novel target for therapeutic strategies.

46 development of potential Alzheimer's disease therapeutic strategies.

47 ich is highlighted as a target for potential therapeutic strategies.

48 ss may facilitate the development of new T2D therapeutic strategies.

49 and a new foundation for the development of therapeutic strategies.

50 chanisms underlying AS and identifying novel therapeutic strategies.

51 l gene circuits and the design of cell-based therapeutic strategies.

52 d BMT, and must be considered when designing therapeutic strategies.

53 and has a crucial impact in developing novel therapeutic strategies.

54 ng force in developing future diagnostic and therapeutic strategies.

55 g the importance of developing effective new therapeutic strategies.

56 ighly lethal disease in critical need of new therapeutic strategies.

57 xaminations that are available to help guide therapeutic strategies.

58 se findings may guide the development of new therapeutic strategies.

59 r the development of improved preventive and therapeutic strategies.

60 mechanistic understanding and development of therapeutic strategies against AMD.

61 ns regarding the design of novel miRNA-based therapeutic strategies against angiogenesis.

62 standing of disease pathogenesis and develop therapeutic strategies against LAM.

63 and suggest targeting Arhgef1 as a potential therapeutic strategy against atherosclerosis.

64 mechanisms and provides a novel combination therapeutic strategy against MCL and other B-cell malign

65 errantly accumulated Rock2 may be a suitable therapeutic strategy against neurodegeneration.

66 2 and Src inhibitors represents an effective therapeutic strategy against ovarian cancer progression.

67 hy and impulsivity, and the need for a joint therapeutic strategy against them.

68 ve broad implications for the development of therapeutic strategies aimed at altering natural Ab leve

69 ch in the AD field focused on developing new therapeutic strategies aimed at blocking its activation.

70 in the neurobiology of tau, and suggest that therapeutic strategies aimed at inhibiting this protease

71 G-AP and it could promote the development of therapeutic strategies and advance the mechanism researc

72 ded progress toward the development of novel therapeutic strategies and are summarized.

73 ially powerful system to identify additional therapeutic strategies and disease-relevant genes in CRC

74 as a basis for the development of innovative therapeutic strategies and for the selection of cattle w

75 pharmacologic data that can reinforce known therapeutic strategies and identify novel drugs and drug

76 ibiting AXL for the development of different therapeutic strategies and inhibitors.

77 disease expression, to develop time-specific therapeutic strategies and to refine existing treatments

78 eflect upon whether the current research and therapeutic strategies are appropriate and whether resou

79 Thus more tailored prevention and therapeutic strategies are still lacking.

80 a significant challenge for preventative or therapeutic strategies based on broadly neutralizing ant

81 he ultimate vision of synchronising tailored therapeutic strategies based on specific diagnostic data

82 Thus, our findings suggest novel therapeutic strategies based on the blockade of this CD8

83 c spread, thus providing the rationale for a therapeutic strategy based on PIN1 inhibition.

84 Thus, we also review therapeutics strategies being utilized or developed to l

85 ral to a variety of biological processes and therapeutic strategies, but visualizing the molecular-le

86 dings may facilitate development of improved therapeutic strategies by targeting the p62/NF-kappaB pa

87 Slug/ZEB2 signaling, and provide a potential therapeutic strategy by targeting miR-218 in NSCLC.

88 he novel targets for regional preventive and therapeutic strategies development.

89 that miR-26a delivery might not be a viable therapeutic strategy due to the potential deleterious on

90 o healing impairment in RDEB, and highlights therapeutic strategies for ameliorating healing.

91 g pathways for amyloid assembly could impact therapeutic strategies for as many as 50 disease states.

92 P2A and inhibit proteasome activity as novel therapeutic strategies for asthma.

93 RT1-small-molecule-activator/inhibitor-based therapeutic strategies for cancers.

94 ation that may open up possibilities for new therapeutic strategies for cardiovascular diseases.

95 This work suggests new therapeutic strategies for certain human movement disord

96 r the development of improved preventive and therapeutic strategies for chronic progressive kidney di

97 l cellular model may be useful in developing therapeutic strategies for conditions involving mitochon

98 senchymal stromal cells (MSCs) are promising therapeutic strategies for coronary artery disease; howe

99 ructive macrophages will potentially uncover therapeutic strategies for dysferlinopathies.

100 uld be a target for the development of novel therapeutic strategies for GVHD treatment.

101 ection, and regarding optimal prevention and therapeutic strategies for infected mothers and neonates

102 emonstrate that the development of efficient therapeutic strategies for IPF is an important future en

103 These findings might lead to new therapeutic strategies for liver disease-associated symp

104 New therapeutic strategies for malignant mesothelioma are ur

105 Several therapeutic strategies for mitochondrial disorders are n

106 The majority of therapeutic strategies for mycosis require the protracte

107 tial of HSJ1, and deserve future interest as therapeutic strategies for neurodegenerative disease.

108 athway in CNS inflammation and suggest novel therapeutic strategies for neuroinflammatory disorders.

109 suppression, there is an urgent need for new therapeutic strategies for patients with end-stage liver

110 the development of effective mechanism-based therapeutic strategies for patients with histiocytic dis

111 may open new avenues for the development of therapeutic strategies for progressive MS.

112 gy and towards development of early targeted therapeutic strategies for prostate cancer.

113 We propose that future therapeutic strategies for renal fibrosis should include

114 d support the development of immune-targeted therapeutic strategies for reversing cell loss associate

115 doxorubicin or dinaciclib provided effective therapeutic strategies for SCLC.

116 de clinical insights into potential targeted therapeutic strategies for skeletal disorders associated

117 Therapeutic strategies for skeletal muscle fibrosis shou

118 ill be critical for the development of novel therapeutic strategies for the treatment of obesity and

119 innings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of

120 f the key obstacles to developing successful therapeutic strategies for these tumors is the striking

121 CNL will help in the development of improved therapeutic strategies for this patient population.

122 cell type must be considered when developing therapeutic strategies for treating ALS.SIGNIFICANCE STA

123 n normal and malignant HSPCs and suggest new therapeutic strategies for treating CBL(mut) myeloid mal

124 ith our long term goals of discovering novel therapeutic strategies for treating neurological disorde

125 These results suggest new therapeutic strategies for treatment of eczema vaccinatu

126 ld facilitate the development of much-needed therapeutic strategies for treatment of inflammatory and

127 types and genotypes in designing nonsurgical therapeutic strategies for uterine leiomyoma.

128 n, and targeting IRF4 represents a potential therapeutic strategy for achieving transplant acceptance

129 mal stem/stromal cells represent a promising therapeutic strategy for acute respiratory distress synd

130 y synaptic dysfunction would be an effective therapeutic strategy for AD.

131 reveal alphavbeta5 inhibition as a promising therapeutic strategy for AKI.

132 ting hBM34+ cell transplantation as a future therapeutic strategy for ALS patients.

133 Here we present a promising alternative therapeutic strategy for ALS that involves targeting ata

134 n of mitochondrial dynamics as an innovative therapeutic strategy for Alzheimer's disease.

135 AML drug sensitivity, which provides a novel therapeutic strategy for AML treatment.

136 g CD70/CD27 signaling represents a promising therapeutic strategy for AML.

137 of IL-21 signaling representing a potential therapeutic strategy for autoantibody-driven diseases su

138 AURKA inhibitors may provide a therapeutic strategy for biomarker-driven clinical studi

139 at manipulating Galpha13 activity might be a therapeutic strategy for bone diseases.

140 periodontal ligament in vitro, and suggest a therapeutic strategy for bone regeneration in the future

141 modulating PGRN level has been proposed as a therapeutic strategy for both diseases.

142 tion of the MAPK/mTOR pathway as a potential therapeutic strategy for CRAF-fusion-driven tumors.

143 rgeting SKP2-EZH2 pathway may be a promising therapeutic strategy for CRPC treatment.

144 ellular redox homeostasis, is advocated as a therapeutic strategy for diseases with severely impaired

145 , miR-28 replacement is uncovered as a novel therapeutic strategy for DLBCL and BL treatment.

146 ion toxin proteins could form the basis of a therapeutic strategy for eliminating latently infected c

147 KDM1A using NCL-1 and NCD-38 is a promising therapeutic strategy for elimination of GSCs.

148 ting of FOXO1 therefore provides a potential therapeutic strategy for elimination of stem cells at bo

149 These results reveal a new therapeutic strategy for GCD2; this method may also be a

150 -associated DNA repair may represent a novel therapeutic strategy for gliomas.

151 potential utility of targeting TUG1/HK2 as a therapeutic strategy for HCC.

152 huntingtin-mediated neurotoxicity might be a therapeutic strategy for HD.

153 regulation of the tumor immunity provides a therapeutic strategy for highly lethal ovarian cancer.

154 HIV-1 latency, which may lead to a potential therapeutic strategy for HIV persistence by targeting th

155 s with chromosome deletions, and a potential therapeutic strategy for human aneuploidy diseases invol

156 expression should be investigated as a novel therapeutic strategy for IPF.

157 pathways continues to attract attention as a therapeutic strategy for KRAS-driven tumors.

158 le SSTR subtypes that offer actionable chemo-therapeutic strategy for management of symptomatic, unre

159 We thus reveal a novel therapeutic strategy for neurological disorders that are

160 lues of LncHIFCAR in prognosis and potential therapeutic strategy for oral carcinoma.

161 of ovarian carcinomas and may provide a new therapeutic strategy for ovarian cancer.

162 Therefore, lorlatinib might be an effective therapeutic strategy for patients with ALK-positive NSCL

163 nhibition of this pathway represents a novel therapeutic strategy for PDAC treatment.

164 bly, C3 intervention is emerging as a viable therapeutic strategy for renal disorders with predominan

165 inhibition of TR locally in the retina is a therapeutic strategy for retinal degeneration management

166 ntation of pulp regeneration as an effective therapeutic strategy for root canal therapy, especially

167 indicating miR-92a inhibition as a potential therapeutic strategy for RPGN.

168 ate that beta-agonist stimulation is a novel therapeutic strategy for SBMA.

169 nterneuron transplants may represent a novel therapeutic strategy for schizophrenia.

170 that pan-RAS inhibition may be an effective therapeutic strategy for some cancers and that structure

171 and could therefore be exploited as a useful therapeutic strategy for stroke.

172 cumulation of autophagosomes may represent a therapeutic strategy for tackling such diseases.

173 r and biological insights inform a potential therapeutic strategy for targeting aggressive mesenchyma

174 emarkably, our data reveal a novel potential therapeutic strategy for targeting both the cytoplasmic

175 These findings identify a novel therapeutic strategy for the clinical treatment of cysti

176 e, suggesting that this could be a potential therapeutic strategy for the prevention of therapeutic e

177 ion, provides a prime 'collateral lethality' therapeutic strategy for the treatment of a substantial

178 ylase activity itself could serve as a novel therapeutic strategy for this aggressive subtype of huma

179 due to loss of MTM1, providing an attractive therapeutic strategy for this disease.

180 antagonist cilengitide, providing a targeted therapeutic strategy for this unique subset of GBM tumor

181 eins for degradation represents an effective therapeutic strategy for TNBC treatment.

182 o, Vertex Pharmaceuticals, Boston, MA), as a therapeutic strategy for treating pulmonary edema.

183 ngiogenesis therefore represents a promising therapeutic strategy for treating these disorders, highl

184 activated macrophages could be a successful therapeutic strategy for treatment of PIRI including CLI

185 Current therapeutic strategies have not provided constant benefi

186 O-GlcNAcylation and also provides a possible therapeutic strategy, i.e., by increasing O-GlcNAcylatio

187 iation and the development of diagnostic and therapeutic strategies.IMPORTANCE Papillomaviruses (PVs)

188 dothelial NO production represent reasonable therapeutic strategies in addition to the treatment of e

189 hermore, they provide biologic rationale for therapeutic strategies in AML targeting the microenviron

190 ary defense mechanisms should help to inform therapeutic strategies in an ICU setting.

191 with the aid of rMSCs can be used to develop therapeutic strategies in bone tissue engineering with n

192 ic pathways may create opportunities for new therapeutic strategies in cancer.

193 rts on the implementation of stem cell-based therapeutic strategies in CHD.

194 t the 'nano'-scale is providing exciting new therapeutic strategies in clinical management of cancer

195 als largely support the current risk-adapted therapeutic strategies in early-stage HL.

196 atopoietic disease in humanized mice and for therapeutic strategies in genetic blood disorders.

197 erence approaches are emerging as attractive therapeutic strategies in neurological diseases.

198 ature of AA supporting the need for systemic therapeutic strategies in severe patients.

199 hich would set the basis for preventative or therapeutic strategies in T1D.

200 eukocytes could guide possible host-directed therapeutic strategies in TBM.

201 st in miRNA-based therapies, may offer novel therapeutic strategies in the treatment of gastrointesti

202 describe how autophagy upregulation may be a therapeutic strategy in a wide range of neurodegenerativ

203 OX2-driven mitochondrial transfer as a novel therapeutic strategy in AML.

204 e data suggest that targeting RIPK1 may be a therapeutic strategy in both AD and FTD.

205 ins BrdT and Brd4 is emerging as a promising therapeutic strategy in contraception, cancer, and heart

206 at augmenting mCa(2+) efflux may be a viable therapeutic strategy in disease.

207 Our findings suggest Cav-1 as a novel therapeutic strategy in disorders involving impaired hip

208 ng these RBP complexes might provide a novel therapeutic strategy in leukemia.

209 on, suggesting PI(3)P kinase inhibitors as a therapeutic strategy in Lowe syndrome.

210 ell receptor (BCR) signaling is a successful therapeutic strategy in mature B-cell malignancies.

211 eting of the LGR4/R-spondin interaction as a therapeutic strategy in MM.

212 NRP1 or its NCD interactors may be a useful therapeutic strategy in neovascular disease to reduce VE

213 tion represents an attractive, albeit toxic, therapeutic strategy in oncology.

214 light the potential of SIRT1 activation as a therapeutic strategy in progressive, fibrotic kidney dis

215 ate metabolism in glioma cells, suggesting a therapeutic strategy in this setting.

216 se findings establish p90RSK inhibition as a therapeutic strategy in treatment-resistant melanoma and

217 echanisms necessary to optimize delivery and therapeutic strategies, in order to design the next gene

218 Cs) are regularly utilized for translational therapeutic strategies including cell therapy, tissue en

219 heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge.

220 One therapeutic strategy is to generate Coenzyme A precursor

221 itive leukemia in mice, suggesting that this therapeutic strategy may be useful in patients who devel

222 positive side, recent findings suggest that therapeutic strategies modulating microglial activation

223 inhibition of extracellular PPIA as a novel therapeutic strategy, not only for SOD1-linked ALS, but

224 ney cancer growth and provide an alternative therapeutic strategy of improving the efficacy of multik

225 our observations, we propose an alternative therapeutic strategy of silencing either of the PKM isof

226 present a novel intracellular antiadrenergic therapeutic strategy protecting the heart from arrhythmi

227 es multifactorial ailments for which current therapeutic strategies remain insufficient to broadly ad

228 Any therapeutic strategy should determine if there is an eff

229 s or predict a patient's response to various therapeutic strategies, so as to enable personalized or

230 ient tools for in utero cord transduction in therapeutic strategies such as for treatment of inherite

231 c basis of L-ORD has implications for future therapeutic strategies such as gene augmentation therapy

232 ance of T-cell homeostasis and outline novel therapeutic strategies tailored to manipulate cell death

233 We also propose several therapeutic strategies targeting Bregs for better manage

234 Therapeutic strategies targeting DNA repair pathway defe

235 New therapeutic strategies targeting mitochondria protection

236 n the proinflammatory response to TNF-alpha, therapeutic strategies targeting this transcription fact

237 guide the rational design of more effective therapeutic strategies targeting upper and lower airways

238 as HOXA9 and MEIS1 In light of developing a therapeutic strategy targeting this complex, understandi

239 mplications include a need for combinatorial therapeutic strategies that account for the discrete dis

240 endencies might be exploited to devise novel therapeutic strategies that aim at disrupting essential

241 The development of therapeutic strategies that aim to blunt hypermetabolism

242 Furthermore, therapeutic strategies that aim to induce these pathways

243 glaucoma, and accelerate the development of therapeutic strategies that aim to protect these cells.

244 an important consideration in the context of therapeutic strategies that combine genotoxic agents wit

245 Therapeutic strategies that combine MEK inhibitors with

246 cells is an essential step toward developing therapeutic strategies that improve nerve regeneration a

247 tions is critical for the development of new therapeutic strategies that resolve infectious inflammat

248 esults support the investigation of targeted therapeutic strategies that seek to address the alterati

249 function and will enable us to develop novel therapeutic strategies that specifically target epigenet

250 t outcome and a need for rationally designed therapeutic strategies that target disease biology.

251 These findings have implications for therapeutic strategies that target IL-17, because these

252 By simulating therapeutic strategies that target multiple nodes of the

253 e the foundation for the development of CRPC therapeutic strategies that would be highly efficient wh

254 lly effective and translationally applicable therapeutic strategy that involves nonviral siRNA delive

255 Thus, a combinatorial therapeutic strategy that targets the PI3K-mTOR pathway

256 Previously, we defined a novel therapeutic strategy that used the bladder cell exfolian

257 orders and their potential to become a novel therapeutic strategy that will improve the efficiency of

258 idual's repertoire; and they support the new therapeutic strategies this concept introduces.SIGNIFICA

259 er, these observations may aid in developing therapeutic strategies to improve the outcome of schizop

260 Novel therapeutic strategies to overcome proteasome inhibitor

261 llular matrix mineralization can be possible therapeutic strategies to prevent ectopic cartilage calc

262 ors to uncover their biology and develop new therapeutic strategies to protect the graft.

263 for designing cost-effective preventive and therapeutic strategies to slow the epidemic in populatio

264 ervations have encouraged the development of therapeutic strategies to treat and prevent telomere-ass

265 DA neurotransmission and relevance to novel therapeutic strategies to treat reduced motivation and m

266 Therefore, we lack efficient therapeutic strategies to treat this pathology.

267 esults suggest inhibition of PLD4 as a novel therapeutic strategy to activate protease-mediated degra

268 ase II inhibitors may result in a beneficial therapeutic strategy to ameliorate contractile dysfuncti

269 e growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimm

270 dings suggest HDAC6 inhibition is a rational therapeutic strategy to be implemented in combination th

271 Finally, the model predicted a therapeutic strategy to deliver nucleotide receptor agon

272 dels, and suggests a potential combinatorial therapeutic strategy to efficiently treat SMA.

273 creasing proteasome activity may be a useful therapeutic strategy to enhance the generation of memory

274 udy identifies SOCS1 mimicking as a feasible therapeutic strategy to halt the onset and progression o

275 BCL-2/BCL-XL inhibitors as a mechanism-based therapeutic strategy to improve TNBC treatment.

276 7R antagonism in vivo represents a promising therapeutic strategy to limit salivary gland inflammatio

277 ing and their bioactivity may be a promising therapeutic strategy to limit the development of an endo

278 f CICI and that PFT-mu may offer a tractable therapeutic strategy to limit this common side-effect of

279 hondrial actions and could represent a novel therapeutic strategy to minimize the detrimental clinica

280 Thus, our study provides a novel therapeutic strategy to optimize MK-1775 treatment effic

281 ggest that targeting of GPX4 may represent a therapeutic strategy to prevent acquired drug resistance

282 .SIGNIFICANCE STATEMENT To date, there is no therapeutic strategy to promote synaptic recovery in the

283 Targeting fibrinogen may be an upstream therapeutic strategy to promote the regenerative potenti

284 ncement of NAMPT activity as a promising new therapeutic strategy to protect against anticancer drug-

285 interneuron transplants may be an effective therapeutic strategy to reduce hippocampal hyperactivity

286 Vimentin targeting may be an important therapeutic strategy to reduce metastases in patients wi

287 limination of senescent cells may be a novel therapeutic strategy to reduce steatosis.

288 ting resolution using SPM represents a novel therapeutic strategy to resolve chronic tendon inflammat

289 ial to activate latent plasticity as a novel therapeutic strategy to restore synaptic strength.

290 pathway may therefore represent a potential therapeutic strategy to restore the BRB.

291 Fi-resistant melanoma may represent a viable therapeutic strategy to restore vemurafenib sensitivity,

292 m the paper "BET bromodomain inhibition as a therapeutic strategy to target c-Myc".

293 inhibition of PDHK4 could represent a novel therapeutic strategy to target KRAS mutant colorectal an

294 local loss of DDR, and identify a potential therapeutic strategy to target SETD2-mutant leukemias.

295 FN-beta reduces CSC properties, suggesting a therapeutic strategy to treat drug-resistant, highly agg

296 CDK4/6 targeting is a promising therapeutic strategy under development for various tumor

297 Therapeutic strategies using anti-PD-1-blocking antibodi

298 A therapeutic strategy was developed to deliver enhanced P

299 To translate our findings into a therapeutic strategy, we knock down SLN expression in 1-

300 ranslated to only limited success; effective therapeutic strategies will need also to target elements